[Antiarrhythmic effect of TJ0711]
Abstract:
To study the antiarrhythmic effect of the newly developed alpha/beta-blocker TJ0711, a variety of animal models of arrhythmia were induced by CaCl2, ouabain and ischemia/reperfusion. Glass microelectrode technique was used to observe action potentials of right ventricular papillary muscle of guinea pig. The onset time of arrhythmia induced by CaCl2 was significantly prolonged by TJ0711 at 0.75, 1.5 and 3 mg x kg(-1) doses. TJ0711 (1.5 and 3 mg x kg(-1)) can significantly shorten the ventricular tachycardia (VT) and ventricular fibrillation (VF) duration, the incidence of VF and mortality were significantly reduced. On ischemia-reperfusion-induced arrhythmic model, TJ0711 (0.25, 0.5, 1 and 2 mg x kg(-1)) can significantly reduce the ventricular premature contraction (PVC), VT, VF incidence, mortality, arrhythmia score with a dose-dependent manner. At the same time, rats serum lactate dehydrogenase (LDH) and creatine kinase (CK) activities decreased significantly by TJ0711 (1 and 2 mg x kg(-1)). Ouabain could cause arrhythmia in guinea pigs, when TJ0711 (0.375, 0.75, 1.5 and 3 mg x kg(-1)) was given, the doses of ouabain inducing a variety of arrhythmia PVC, VT, VF, cardiac arrest (CA) were significantly increased with a dose-dependent manner. In the TJ0711 0.1-30 micromol x L(-1) concentration range, guinea pig right ventricular papillary muscle action potential RP (rest potential), APA (action potential amplitude) and V(max) (maximum velocity of depolarization) were not significantly affected. APD20, APD50 and APD90 had a shortening trend but no statistical difference with the increase of TJ0711 concentration. TJ0711 has antiarrhythmic effect on the sympathetic nerve excitement and myocardial cell high calcium animal arrhythmia model. Myocardial action potential zero phase conduction velocity and resting membrane potential were not inhibited by TJ0711. APD20, APD50 and APD90 were shortened by TJ0711 at high concentration. Its antiarrhythmic action mechanism may be besides the action of blocking beta1 receptor, may also have a strong selective blocking action on alpha1 receptor and reducing intracellular calcium concentration.
Insights
The novel alpha/beta-blocker TJ0711 demonstrates significant antiarrhythmic effects in animal models. It reduces the incidence and duration of various arrhythmias, including ventricular tachycardia and fibrillation, without negatively impacting myocardial action potentials.
Area of Science:
- Pharmacology
- Cardiovascular Research
- Drug Discovery
Background:
- Arrhythmia remains a significant cause of mortality worldwide.
- Novel therapeutic agents with improved efficacy and safety profiles are needed.
- Alpha/beta-blockers offer potential antiarrhythmic properties.
Purpose of the Study:
- To evaluate the antiarrhythmic efficacy of the newly developed alpha/beta-blocker, TJ0711.
- To investigate the effects of TJ0711 on various animal models of cardiac arrhythmia.
- To explore the potential mechanisms underlying TJ0711's antiarrhythmic action.
Main Methods:
- Induction of arrhythmias using CaCl2, ouabain, and ischemia/reperfusion in animal models.
- Measurement of cardiac action potentials using the glass microelectrode technique in guinea pig right ventricular papillary muscles.
- Assessment of biochemical markers such as lactate dehydrogenase (LDH) and creatine kinase (CK) in rat serum.
Main Results:
- TJ0711 significantly prolonged the onset of CaCl2-induced arrhythmia and dose-dependently reduced ventricular tachycardia (VT), ventricular fibrillation (VF), incidence, and mortality in ischemia-reperfusion models.
- TJ0711 increased the ouabain doses required to induce various arrhythmias (PVC, VT, VF, CA) in a dose-dependent manner.
- TJ0711 did not significantly affect resting potential, action potential amplitude, or maximum depolarization velocity but showed a trend towards shortening action potential duration at high concentrations.
Conclusions:
- TJ0711 exhibits significant antiarrhythmic effects across multiple animal models.
- Its mechanism may involve beta1 receptor blockade, selective alpha1 receptor blockade, and reduction of intracellular calcium concentration.
- TJ0711 represents a promising candidate for the treatment of cardiac arrhythmias.
More Related Videos
Related Concept Videos
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Mechanism of Cardiac Arrhythmias
Dysrhythmias IV: Characteristics of Bradyarrhythmias


